What is your max, min, and average forecast for Denosumab's US revenue in 2015? Explain your assumptions
Fantastic news! We've Found the answer you've been seeking!
Question:
What is your max, min, and average forecast for Denosumab's US revenue in 2015? Explain your assumptions clearly and show the estimates in your spreadsheet.
2. What are some factors and assumptions that would impact your forecast?
3. What are some other data points you would capture in order to improve the confidence level in your forecast?
Transcribed Image Text:
"Our job is quite simple," explained Jennifer Fry, project manager at Oakdale Strategy Group, a strategy consulting firm based in Chicago. It was a cold day in early February 2011, and Fry was meeting with her team. "We've been asked to develop a forecast for denosumab for 2015," she continued. "Our client is one of the world's largest pharmaceutical firms. The senior executives there are taking a close look at acquiring Amgen and want an outside opinion about denosumab." Steven Meyers, a partner at the firm, quickly jumped in. "This is an incredibly high-profile assignment because the value of Amgen is closely tied to the revenue forecast for denosumab. We've got an important client and a very important project. Let's nail this one." Amgen Amgen was one of the world's leading biotechnology companies, with more than 17,000 employees and almost $15 billion in revenue. The company was founded in 1980 under the name Applied Molecular Genetics and assumed the name Amgen in 1983. Amgen was highly profitable; in 2009 it had net income of $4.6 billion on revenues of $14.6 billion (see Exhibit 1). In 2010 Amgen had ten drugs approved for sales in the United States. The most important of these were Aranesp and Epogen, for anemia; Enbrel, for arthritis; and Neulasta, for febrile neutropenia, a condition associated with chemotherapy (see Exhibit 2). Despite its considerable success, Amgen was in a difficult position in 2011; the company's core products were not growing and Aranesp was declining sharply. In addition, patent expiration issues loomed. As a result, Amgen's stock was not performing well; it had peaked in 2005 at more than $85 per share but had declined to about $55 per share five years later. Amgen's most promising new product was denosumab, a fully human monoclonal antibody designed to treat osteoporosis. Amgen began working on the molecule in 1994 and finally launched it sixteen years later under the brand names Prolia and Xgeva. As CEO Kevin Sharer wrote in Amgen's 2009 annual report, "Doctors and experts who have reviewed the data are "Our job is quite simple," explained Jennifer Fry, project manager at Oakdale Strategy Group, a strategy consulting firm based in Chicago. It was a cold day in early February 2011, and Fry was meeting with her team. "We've been asked to develop a forecast for denosumab for 2015," she continued. "Our client is one of the world's largest pharmaceutical firms. The senior executives there are taking a close look at acquiring Amgen and want an outside opinion about denosumab." Steven Meyers, a partner at the firm, quickly jumped in. "This is an incredibly high-profile assignment because the value of Amgen is closely tied to the revenue forecast for denosumab. We've got an important client and a very important project. Let's nail this one." Amgen Amgen was one of the world's leading biotechnology companies, with more than 17,000 employees and almost $15 billion in revenue. The company was founded in 1980 under the name Applied Molecular Genetics and assumed the name Amgen in 1983. Amgen was highly profitable; in 2009 it had net income of $4.6 billion on revenues of $14.6 billion (see Exhibit 1). In 2010 Amgen had ten drugs approved for sales in the United States. The most important of these were Aranesp and Epogen, for anemia; Enbrel, for arthritis; and Neulasta, for febrile neutropenia, a condition associated with chemotherapy (see Exhibit 2). Despite its considerable success, Amgen was in a difficult position in 2011; the company's core products were not growing and Aranesp was declining sharply. In addition, patent expiration issues loomed. As a result, Amgen's stock was not performing well; it had peaked in 2005 at more than $85 per share but had declined to about $55 per share five years later. Amgen's most promising new product was denosumab, a fully human monoclonal antibody designed to treat osteoporosis. Amgen began working on the molecule in 1994 and finally launched it sixteen years later under the brand names Prolia and Xgeva. As CEO Kevin Sharer wrote in Amgen's 2009 annual report, "Doctors and experts who have reviewed the data are
Expert Answer:
Answer rating: 100% (QA)
Max Min and Average Forecast for Denosumabs US Revenue in 2015 To estimate Denosumabs US revenue in 2015 you would typically start with available hist... View the full answer
Related Book For
Fundamentals of Corporate Finance
ISBN: 978-0133400694
1st canadian edition
Authors: Jonathan Berk, Peter DeMarzo, Jarrad Harford, David A. Stangeland, Andras Marosi
Posted Date:
Students also viewed these general management questions
-
Planning is one of the most important management functions in any business. A front office managers first step in planning should involve determine the departments goals. Planning also includes...
-
The Crazy Eddie fraud may appear smaller and gentler than the massive billion-dollar frauds exposed in recent times, such as Bernie Madoffs Ponzi scheme, frauds in the subprime mortgage market, the...
-
Read the case study "Southwest Airlines," found in Part 2 of your textbook. Review the "Guide to Case Analysis" found on pp. CA1 - CA11 of your textbook. (This guide follows the last case in the...
-
Read each case carefully and, as determined in the Internal Revenue Code of Puerto Rico, identify the deductions, calculate the amount of deductions and what the determined contribution would be. and...
-
An individual has $35,000 invested in a stock with a beta of 0.8 and another $40,000 invested in a stock with a beta of 1.4. If these are the only two investments in her portfolio, what is her...
-
A chemical company wishes to mix three elements (E, F, and G) to create three alloys (X, Y, and Z). The costs of The elements are as shown in the following table. To maintain the required quality for...
-
The efficiency of a light source is the percentage of its energy input that gets radiated as visible light. If some of the blue light in an LED is used to cause a fluorescent material to glow, A. The...
-
Using the information in Problem 3, calculate the sample size needed if the standard time estimate is to be within 5 percent of the true mean 99 percent of the time. Calculate the percentage increase...
-
How do influencers and thought leaders strategically employ personal branding and persuasive communication to cultivate loyal followings and effect social change?
-
Packaging Corporation of America produces containerboard and white papers. WestRock Co. manufactures paper products and corrugated products. Financial statement data for these two companies follow:...
-
A U.S. firm sells merchandise today to a British company for 100,000. The current exchange rate is $1.38/, the account is payable in three months, and the firm chooses to hedge by borrowing 98,765.43...
-
In India, Sanjay worked as an accountant. Upon his immigration to Canada, he learned that his accounting designation would not be recognized in this country unless he writes additional exams....
-
Project X Z Year 0 $(600.00) $(950.00) 1 $200.00 $900.00 2 $300.00 $500.00 3 $450.00 Payback Discounted payback NPV IRR MIRR Crossover Mutually exclusive Independent i=12% What is the payback of X?...
-
Bob took a $500 cash advance from his credit card. The credit card company charges 25% interest that compounds daily. How much will Bob owe in a year, assuming 365 days?
-
Given the spot rates as s1 = 18%, s2=19%, s3-21%, s4-21%, and s5-18% calculate the following values rounded to 2 digits: Future rates f(1,2)= | %, f(2,3)= and d(1,5) = %, the short rate r2=[ %, and...
-
The Singer's estimated annual expenses in retirement are $150,000, and their estimated retirement income from Social Security, pensions, and investments is $75,000. To adjust these amounts for...
-
Find the equation of the line with the given properties. Express the equation in general form or slope-intercept form. Perpendicular to the line 2x +y = -9, contains the point (-10,10) DOO The...
-
Use this circle graph to answer following Exercises. 1. What fraction of areas maintained by the National Park Service are designated as National Recreation Areas? 2. What fraction of areas...
-
Why does the part of your loan payment covering interest change over time?
-
How do corporate taxes affect the decision of a firm to retain excess cash?
-
According to the trade-off theory, how should a financial manager determine the right capital structure for a firm?
-
What is an off-by-one error?
-
Will the universality of management continue to be true in the future? Why or why not?
-
Describe what a manager does. How does the work of managers differ from that of nonmanagerial employees?
Study smarter with the SolutionInn App